EcoDrugPlus

Gonadotropin Releasing Hormone Receptor

Ensembl ID : ENSANAG00000020453
Gene Symbol: GNRHR
4 Cross references
242 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Growth Hormone Releasing Hormone Receptor

Ensembl ID : ENSANAG00000023004
Gene Symbol: GHRHR
4 Cross references
193 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSANAG00000020011
Gene Symbol: GHSR
4 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSANAG00000021198
Gene Symbol: GUCY1A1
4 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSANAG00000023296
Gene Symbol: GUCY1A2
4 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSANAG00000030916
Gene Symbol: GUCY1B1
4 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Heat Shock Protein Hsp 90-Alpha-Like

Ensembl ID : ENSANAG00000021089
Gene Symbol: LOC105709072
2 Cross references
238 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Heat Shock Protein Hsp 90-Alpha-Like

Ensembl ID : ENSANAG00000036934
Gene Symbol: LOC105707837
2 Cross references
230 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Heat Shock Protein Hsp 90-Beta Pseudogene

Ensembl ID : ENSANAG00000033764
Gene Symbol: LOC105714240
1 Cross references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

High Mobility Group Box 1

Ensembl ID : ENSANAG00000033984
Gene Symbol: HMGB1
4 Cross references
260 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H1

Ensembl ID : ENSANAG00000031051
Gene Symbol: HRH1
2 Cross references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H2

Ensembl ID : ENSANAG00000028688
Gene Symbol: HRH2
4 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).